ENETS 2024: Discover the multi-disciplinary discussion with NET thought leaders

Dr. Thorvardur R. Halfdanarson is a Medical Oncologist and Professor at Mayo Clinic, in Rochester (Minnesota, USA) specializing in gastrointestinal malignancies, with a focus on neuroendocrine tumors, and the Chair of the Hepato-Pancreatic-Biliary Disease Group, Co-Chair of the Pancreatic and Neuroendocrine Tumor Board, and Associate Medical Director of the Cancer Clinical Trials Office at Mayo Clinic. His clinical expertise spans the management of various neuroendocrine, hepatobiliary and pancreatic cancers, colorectal cancer, and cancers of unknown primary sites. Dr. Halfdanarson is involved in impactful research on neuroendocrine tumors, ranging from epidemiology to novel therapeutic interventions in clinical trials. Serving as the Director of the Advanced GI Oncology Fellowship and previously the assistant program director for the Hematology/Oncology fellowship program at Mayo Clinic, in Rochester (Minnesota, USA), he has garnered numerous awards for contributions to the education of residents and fellows. Dr. Halfdanarson is the current president of the North American Neuroendocrine Tumor Society (NANETS), a member of the NET Guidelines Panel at the National Comprehensive Cancer Network (NCCN), and the Co-Chair of the Neuroendocrine Tumor Group at the Alliance for Clinical Trials in Oncology.

Dr. Paola Anna Erba is the Director of Nuclear Medicine at Hospital Papa Giovanni XXIII in Bergamo (Italy), and Professor of Nuclear Medicine at the University of Milan Bicocca. She is also collaborating with the Nuclear Medicine and Molecular Imaging Department at the University Medical Center in Groningen, The Netherlands, where she hold a zero position. Active member of the Italian Association of Nuclear Medicine (AIMN) and the European Association of Nuclear Medicine (EANM), Dr. Erba is serving as President elect of EANM for 2023-2025. Her expertise lies in biological investigations of cancer and inflammation markers, with a focus on stromal antigens and epithelial-mesenchymal transition. Dr. Erba's work includes the preclinical development, validation and early in human clinical trials of new radiopharmaceuticals and of imaging, particularly in the field of cardiovascular infection-inflammation and cancer, through standard imaging techniques and new molecular imaging agents.

Dr. Julien Hadoux is an attending physician at the endocrine oncology unit of Gustave Roussy cancer center in Villejuif (France), and the co-coordinator of the French national network on refractory thyroid cancer (ENDOCAN-TUTHYREF). He is a Member of the French endocrine tumor study group (GTE), the International Thyroid Oncology Group (ITOG) as well as the American Thyroid Association (ATA). His main long-term research interests focus on neuroendocrine neoplasia and thyroid carcinomas from a clinical and translational point of view. He is investigator in clinical trials focusing on endocrine tumors and has authored or co-authored more than 100 articles and book chapters in the field.

Dr. Andrea Frilling, Professor of Surgery and Chair in Endocrine Surgery at Imperial College London (UK), is a practicing consultant surgeon focused on translating basic medical research findings into the clinical setting. Her current research lies in the discovery of novel biomarkers in neuroendocrine gastro-entero-pancreatic tumors and their validation during the patient journey. She has conducted comprehensive clinical research on the multimodal management of advanced neuroendocrine tumors.  She was the first to demonstrate that neuroendocrine liver metastases appear in three morphologically distinct growth types, which are outcome-predictive. Based on that she created a treatment algorithm. At Imperial, she has founded an interdisciplinary Centre of Excellence for neuroendocrine tumor management, accredited by the European Neuroendocrine Tumours Society (ENETS).

Dr. Wouter de Herder serves as Professor of Endocrine Oncology at the Department of Internal Medicine, Endocrinology at Erasmus MC Rotterdam Cancer Center (The Netherlands). At the same Center, he has been Head of the ENETS Center of Excellence and Chairman of the multidisciplinary group for the diagnosis and treatment of endocrine tumors. His specialty in the endocrinology field encompasses neuroendocrine tumors, adrenal tumors, and pituitary tumors. He has extensive research experience in the pathogenesis, diagnosis and therapy of adrenal tumors, as well as the pathogenesis, diagnosis and therapy of neuroendocrine tumors, and a history of acromegaly. Since 2004 he has been co-organizer of the Annual Educational Conference and other congresses produced by the European Neuroendocrine Tumor Society (ENETS).